Company profile
Grapefruit USA, Inc.
OTC: GPFT · Healthcare · Drug Manufacturers - Specialty & Generic
#921 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 45GM —SS 32
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, disclosure history · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$5.5M
Employees
9
as of 2026-08-27
Market cap
$71.7k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$589.0k$589.0k2021
Net income-$5.5M-$5.5M2021
Operating income-$2.4M-$2.4M2021
Total assets$2.8M$2.8M2021
Liabilities$8.6M$8.6M2021
Equity-$5.8M-$5.8M2021
Revenue trend
FY2014 – FY2021 · USD
FY14
FY15
FY16
FY18
FY19
FY19
FY20
FY21
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Grapefruit USA, Inc.’s revenue?
Grapefruit USA, Inc. booked $589.0k in FY2021 revenue, contracting 84% year over year — slower than 89% of Healthcare companies we track, at a -934.6% net margin.
Peers · Healthcare
CBD of Denver, Inc.35DCardiff Oncology, Inc.53DPMGC Holdings Inc.29DTheralase Technologies Inc.37DErnexa Therapeutics Inc.43DViropro Inc.——Neighbors
New Castle →Key facts
CEOBradley J. Yourist
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersWilmington, DE
ExchangeOTC: GPFT
Employees9
IPO date2016-06-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.